ArticleFrontiers in oncology2020
Cancer-ID: Toward Identification of Cancer by Tumor-Derived Extracellular Vesicles in Blood.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Ternary MOF-PEDOT: PSS/AuNPs nanocomposite for ultrasensitive electrochemical detection of extracellular vesicles.Mikrochimica acta · 2026Article
- Molecular Analysis of Single Tumor-Derived Extracellular Vesicles with Improved Robustness and Accuracy.Analytical chemistry · 2026Article
- Exploiting the role of milk extracellular vesicles: a comprehensive analysis on isolation methods, characterization, surface modifications, and their therapeutic applications.Journal of nanobiotechnology · 2026Review
- Isolation-free detection of extracellular vesicles using Janus particles.Extracellular vesicles and circulating nucleic acids · 2026Article
- Autophagy and extracellular vesicles mediate cisplatin resistance in oral squamous cell carcinoma with LC3B-II as a potential non-invasive biomarker.Scientific reports · 2025Article
- Review
- Stoichiometric constraints for detection of EV-borne biomarkers in blood.Journal of extracellular vesicles · 2025Review
- On the dilemma of using single EV analysis for liquid biopsy: the challenge of low abundance of tumor EVs in blood.Theranostics · 2025Review
- Multiparametric profiling of HER2-enriched extracellular vesicles in breast cancer using Single Extracellular VEsicle Nanoscopy.Journal of nanobiotechnology · 2024Article
- Review
- Towards IVDR-compliance by implementing quality control steps in a quantitative extracellular vesicle-miRNA liquid biopsy assay for response monitoring in patients with classic Hodgkin lymphoma.Journal of extracellular biology · 2024Article
- Characteristics of Extracellular Vesicles from a High-Grade Serous Ovarian Cancer Cell Line Derived from a Platinum-Resistant Patient as a Potential Tool for Aiding the Prediction of Responses to Chemotherapy.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Advances in extracellular vesicle isolation methods: a path towards cell-type specific EV isolation.Extracellular vesicles and circulating nucleic acids · 2023Review
- Extracellular Vesicles in Coronary Artery Disease.Advances in experimental medicine and biology · 2023Review
- Tools shaping drug discovery and development.Biophysics reviews · 2022Review
- Article
- 4-1BBL-containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells.Blood advances · 2022Article
- Article
- Methodologies to Isolate and Purify Clinical Grade Extracellular Vesicles for Medical Applications.Cells · 2022Review
- Using single-vesicle technologies to unravel the heterogeneity of extracellular vesicles.Nature protocols · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) have great potential as biomarkers since their composition and concentration in biofluids are disease state dependent and their cargo can contain disease-related information. Large tumor-derived EVs (tdEVs, >1 μm) in blood from cancer patients are associated with poor outcome, and changes in their number can be used to monitor therapy effectiveness. Whereas, small tumor-derived EVs (<1 μm) are likely to outnumber their larger counterparts, thereby offering better statistical significance, identification and quantification of small tdEVs are more challenging. In the blood of cancer patients, a subpopulation of EVs originate from tumor cells, but these EVs are outnumbered by non-EV particles and EVs from other origin. In the Dutch NWO Perspectief Cancer-ID program, we developed and evaluated detection and characterization techniques to distinguish EVs from non-EV particles and other EVs. Despite low signal amplitudes, we identified characteristics of these small tdEVs that may enable the enumeration of small tdEVs and extract relevant information. The insights obtained from Cancer-ID can help to explore the full potential of tdEVs in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.